Molecular Subtype
Diffuse Midline Glioma, H3 K27-Altered
CI-CAN-00007581Explore in graph →
Loading cancer entity…
Molecular Subtype
CI-CAN-00007581Explore in graph →
Variants & evidence
32 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| ACVR1 G328E1 | |||||||
| (diagnostic) | Diagnostic | C | Supports Positive | 3 | accepted | EID6091Sequencing (whole genome or exome) was performed on a series of 26 pediatric patients (1.7 to 13.6 years old), 7 had missense mutations in ACVR1. Two patients with G328E mutation were identified. This… (full text at CIViC) PMID 24705252 · Taylor et al., 2014 · Open in CIViC | civic |
| ACVR1 G328V4 | |||||||
| (diagnostic) | Diagnostic | B | Supports Positive | 3 | accepted | EID6955In a study sequencing 61 patients (median age 6.3) with diffuse intrinsic pontine glioma (DIPG), 12 variants affecting ACVR1 were observed. Five patients had G328V within the kinase domain. The ACVR1 … (full text at CIViC) PMID 24705254 · Buczkowicz et al., 2014 · Open in CIViC | civic |
| 〃 | Diagnostic | C | Supports Positive | 2 | accepted | EID10011It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52)… (full text at CIViC) PMID 24705252 · Taylor et al., 2014 · Open in CIViC | civic |
| ALK2 Inhibitor LDN-193189 | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID6092To investigate the specific role of ACVR1 mutations in the context of DIPG, a panel of four DIPG patient-derived primary cultures (and one thalamic paediatric GBM culture harbouring an H3F3A K27M muta… | |
| ACVR1 G328W2 | |||||||
| (diagnostic) | Diagnostic | C | Supports Positive | 2 | accepted | EID10013It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52)… (full text at CIViC) PMID 24705252 · Taylor et al., 2014 · Open in CIViC | civic |
| (predisposing) | Predisposing | D | Supports Predisposition | 3 | submitted | EID6088This mutation is found to be present in about 33% of diffuse intrinsic pontine glioma along with 6 other recurrent heterozygous somatic non-synonymous mis-sense mutations in ACVR1. There lacks evidenc… (full text at CIViC) PMID 26776312 · Pacifici et al., 2016 · Open in CIViC | civic |
| ACVR1 G356D1 | |||||||
| (diagnostic) | Diagnostic | C | Supports Positive | 2 | accepted | EID10015It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52)… (full text at CIViC) PMID 24705252 · Taylor et al., 2014 · Open in CIViC | civic |
| ACVR1 Gain-of-Function1 | |||||||
| (diagnostic) | Diagnostic | B | Supports Positive | 3 | accepted | EID4846Sequencing of 39 pediatric midline high-grade astrocytomas identified 5 patients with ACVR1 mutations. The authors identified an increase in endogenous phospho-SMAD1/5/8 signal in diffuse intrinsic po… (full text at CIViC) PMID 24705250 · Fontebasso et al., 2014 · Open in CIViC | civic |
| ACVR1 Mutation4 | |||||||
| (diagnostic) | Diagnostic | B | Supports Positive | 3 | submitted | EID8014Analysis of 127 paediatric high grade gliomas (HGGs) identified recurrent mutations in ACVR1 exclusively in DIPG. ACVR1 mutations were found in 18 of 57 DIPG tumours (32%) and none of 70 non-brainstem… (full text at CIViC) PMID 24705251 · Wu et al., 2014 · Open in CIViC | civic |
| 〃 | Diagnostic | B | Supports Positive | 3 | accepted | EID10014It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52)… (full text at CIViC) PMID 24705252 · Taylor et al., 2014 · Open in CIViC | civic |
| (prognostic) | Prognostic | B | Supports Better Outcome | 3 | submitted | EID10020It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52)… | |
| ACVR1 R206H1 | |||||||
| (diagnostic) | Diagnostic | C | Supports Positive | 2 | accepted | EID10012It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52)… (full text at CIViC) PMID 24705252 · Taylor et al., 2014 · Open in CIViC | civic |
| ACVR1 R258G1 | |||||||
| (diagnostic) | Diagnostic | C | Supports Positive | 3 | submitted | EID6077It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52)… (full text at CIViC) PMID 24705252 · Taylor et al., 2014 · Open in CIViC | civic |
| ROS1 Fusion1 | |||||||
| Entrectinib | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11849In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (4 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| H3-3A K281 | |||||||
| (diagnostic) | Diagnostic | B | Supports Positive | 3 | submitted | EID9608In this retrospective study, 112 adolescents and young adults (AYA; between 15 and 25 years of age; median 21 years) who had a histopathological diagnosis of high-grade gliomas were analyzed. The H3K2… (full text at CIViC) PMID 32025728 · Roux et al., 2020 · Open in CIViC | civic |
| H3-3A K28M9 | |||||||
| (diagnostic) | Diagnostic | A | Supports Positive | 5 | submitted | EID8626Diffuse midline gliomas, H3 K27M-mutant is a newly defined entity in the 2016 WHO Classification. It primarily occurs in children (but sometimes in adults) and include tumors previously referred to as… (full text at CIViC) PMID 27157931 · Louis et al., 2016 · Open in CIViC | civic |
| 〃 | Diagnostic | B | Supports Positive | 4 | submitted | EID9414Whole exome sequencing was performed on the glioblastomas of 48 pediatric patients (between 3 and 20 years of age). The authors also analyzed gliomas of 784 patients of various ages. The K27M variant … (full text at CIViC) PMID 22286061 · Schwartzentruber et al., 2012 · Open in CIViC | civic |
| (oncogenic) | Oncogenic | B | Supports Oncogenicity | 4 | submitted | EID10600In this study, 91 patients with diffuse intrinsic pontine glioma (DIPG) underwent stereotactic biopsy and were analyzed using histone H3 mutation testing, immunohistochemistry, gene expression profili… | |
| H3-3B K28I1 | |||||||
| (oncogenic) | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID13073Two adult patients with diffuse midline glioma (DMG) harboring a somatic H3F3B K27I mutation were reported. Next-generation sequencing on postoperative tissue was performed using a 539-gene panel (Si… (full text at CIViC) | civic |
| H3C14 K27M1 | |||||||
| (diagnostic) | Diagnostic | C | Supports Positive | 1 | submitted | EID10611Molecular characterisation of a series of 62 diffuse midline gliomas, H3 K27-altered, revealed a single case of a novel histone H3 variant - H3C14 (HIST2H3C) p.K28M (K7M). The variant occurred in the … (full text at CIViC) PMID 26399631 · Castel et al., 2015 · Open in CIViC | civic |
| H3C2 K27M2 | |||||||
| (diagnostic) | Diagnostic | B | Supports Positive | 3 | accepted | EID9546Whole-genome sequencing (WGS) was performed on the diffuse intrinsic pontine gliomas (DIPGs) and matched germline DNA of 7 pediatric patients. Targeted sequencing was performed on an additional 43 DIP… (full text at CIViC) PMID 22286216 · Wu et al., 2012 · Open in CIViC | civic |
| (oncogenic) | Oncogenic | B | Supports Oncogenicity | 2 | accepted | EID13177The recurrent HIST1H3B (now known as H3C2, encoding H3.1) p.K27M mutation was identified in human diffuse intrinsic pontine glioma (DIPG) samples and was associated with a significant global reduction… (full text at CIViC) PMID 23539183 · Lewis et al., 2013 · Open in CIViC | civic |
| WEE1 Overexpression2 | |||||||
| Adavosertib | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID7242Significant WEE1 protein overexpression was detected by IHC in VUMC-DIPG-1 tissue isolated from a patient's frontal lobe. Significant WEE1 protein levels were also found in E98-FM glioma cells. An i… (full text at CIViC) PMID 23270927 · Caretti et al., 2013 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID7243Two mouse xenograft models were used: one of tumor cells from a genetically engineered mouse with a BRAF V600E mutation, and the other using a patient's DIPG cells (SF8628). SF8628 was found to have … (full text at CIViC) PMID 24305702 · Mueller et al., 2014 · Open in CIViC | civic |
Data updated 2 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
PMID 24705252 · Taylor et al., 2014 · Open in CIViC
| civic |
| MEK-1/MEKK-1 Inhibitor E6201 | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID8035Using mouse models, the authors demonstrated that Acvr1G328V arrested the differentiation of oligodendroglial lineage cells to generate high-grade diffuse gliomas. Using a cellular NanoBRET target eng… (full text at CIViC) PMID 32142668 · Fortin et al., 2020 · Open in CIViC | civic |
PMID 24705252 · Taylor et al., 2014 · Open in CIViC
| civic |
| ALK2 Inhibitor LDN-193189 | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID10141Eight ALK2 inhibitors were tested against 3 ACVR1 mutant cell cultures and two wild type cultures. LDN-193189 was the most potent compound with minimal selectivity for the mutant cells. LDN-214117 was… (full text at CIViC) PMID 31098401 · Carvalho et al., 2019 · Open in CIViC | civic |
PMID 26399631 · Castel et al., 2015 · Open in CIViC
| civic |
| (diagnostic) | Diagnostic | B | Supports Positive | 3 | accepted | EID6450Wu et al analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs) by whole genome, whole exome, and/or transcriptome sequencing. In addition t… (full text at CIViC) PMID 24705251 · Wu et al., 2014 · Open in CIViC | civic |
| 〃 | Diagnostic | B | Supports Positive | 3 | accepted | EID6453Whole genome sequencing (WGS) was performed on the diffuse intrinsic pontine gliomas (DIPGs) and matched germline DNA of 7 pediatric patients. Targeted sequencing was performed on an additional 43 DIP… (full text at CIViC) PMID 22286216 · Wu et al., 2012 · Open in CIViC | civic |
| 〃 | Diagnostic | B | Supports Positive | 3 | accepted | EID10605This retrospective study analyzed 91 biopsy-confirmed diffuse intrinsic pontine glioma (DIPG) patients using systematic stereotactic or surgical biopsy at diagnosis. Histone H3 alterations were assess… (full text at CIViC) PMID 26399631 · Castel et al., 2015 · Open in CIViC | civic |
| 〃 | Diagnostic | C | Supports Positive | 4 | submitted | EID9792Zhang et al. (2013) studied 151 tumors from 149 patients. The H3F3A p.K27M variant has been reported in 3 tumors (1.9%). The first sample (SJLGG037_D) was of a less than 3-year-old male patient screen… (full text at CIViC) PMID 23583981 · Zhang et al., 2013 · Open in CIViC | civic |
| (prognostic) | Prognostic | D | Supports Poor Outcome | 3 | submitted | EID10602Diffuse intrinsic pontine glioma (DIPG) patients harboring a H3.3 K27M mutation have a proneural/oligodendroglial phenotype and a prometastatic gene expression with PDGFRA activation. These mutation c… (full text at CIViC) PMID 26399631 · Castel et al., 2015 · Open in CIViC | civic |
| Dordaviprone | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12695In a pooled analysis of five phase I–II trials and an expanded access program of ONC201 (dordaviprone) for recurrent H3 K27M–mutant diffuse midline glioma (NCT02525692, NCT03295396, NCT03416530, NCT03… (full text at CIViC) PMID 38335473 · Arrillaga-Romany et al., 2024 · Open in CIViC | civic |